SANOFI PASTEUR

🇫🇷France

Country: 🇫🇷France

Ownership: Subsidiary

Established: 1990-01-01

Employees: 10K

Market Cap: -

Website: http://www.sanofipasteur.com

Clinical Trials

DTaP-IPV/Hib Vaccine Primary & Booster Vaccinations Versus Co-administration of DTaP-IPV and Hib Vaccine in Japanese Infants

Phase 3

Completed

Conditions: Diphtheria
Tetanus
Bacterial Meningitis
Poliomyelitis
Pertussis

Interventions: Biological: DTaP-IPV vaccine and Hib vaccine
Biological: DTaP-IPV/Hib Combined vaccine

First Posted Date: 2014-10-24

Last Posted Date: 2022-04-25

Lead Sponsor: Sanofi Pasteur, a Sanofi Company

Target Recruit Count: 424

Registration Number: NCT02274285

Study of Fluzone® Quadrivalent, Fluzone® Intradermal, and Fluzone® High-Dose, Influenza Vaccines in Adults

Phase 4

Completed

Conditions: Influenza

Interventions: Biological: Fluzone High Dose vaccine, 2014-2015 formulation
Biological: Fluzone® Quadrivalent vaccine, 2014-2015 formulation
Biological: Fluzone I®ntradermal vaccine, 2014-2015 formulation

First Posted Date: 2014-10-07

Last Posted Date: 2015-10-19

Lead Sponsor: Sanofi Pasteur, a Sanofi Company

Target Recruit Count: 208

Registration Number: NCT02258334

Study of a Single Dose or Two Doses of a Trivalent Inactivated Influenza Vaccine Produced at Shenzhen, China

Phase 4

Completed

Conditions: Influenza

Interventions: Biological: Shenzhen trivalent influenza vaccine (split virion, inactivated) North Hemisphere (NH) formulation

First Posted Date: 2014-08-29

Last Posted Date: 2016-01-29

Lead Sponsor: Sanofi Pasteur, a Sanofi Company

Target Recruit Count: 602

Registration Number: NCT02228980

Safety and Immunogenicity Among Healthy Children Receiving Fluzone® Quadrivalent, Influenza Vaccine

Phase 4

Completed

Conditions: Influenza

Interventions: Biological: Fluzone® Quadrivalent Influenza Vaccine, No Preservative

First Posted Date: 2014-08-21

Last Posted Date: 2015-10-19

Lead Sponsor: Sanofi Pasteur, a Sanofi Company

Target Recruit Count: 60

Registration Number: NCT02222870

Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adolescents

Phase 2

Completed

Conditions: Meningitis
Meningococcal Meningitis
Meningococcal Infections

Interventions: Biological: Meningococcal Polysaccharide (Serogroups A, C, Y, and W135) Tetanus Toxoid Conjugate Vaccine
Biological: Meningococcal (Groups A, C, Y and W135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine

First Posted Date: 2014-07-24

Last Posted Date: 2022-04-04

Lead Sponsor: Sanofi Pasteur, a Sanofi Company

Target Recruit Count: 1715

Registration Number: NCT02199691

DTaP-IPV-Hep B-PRP~T Combined Vaccine Versus DTaP-IPV//PRP~T Combined Vaccine + Hep B Vaccine in Hep B Primed Infants

Phase 3

Completed

Conditions: Diphtheria
Tetanus
Hepatitis B
Haemophilus Influenzae Type b Infection
Pertussis
Poliomyelitis

Interventions: Biological: DTaP-IPV-Hep B-PRP~T combined vaccine
Biological: DTaP-IPV//PRP~T and Hepatitis B vaccine

First Posted Date: 2014-03-24

Last Posted Date: 2017-04-26

Lead Sponsor: Sanofi Pasteur, a Sanofi Company

Target Recruit Count: 310

Registration Number: NCT02094833

Study of SP306 Given Intramuscularly Compared to DT Given Subcutaneously in Japanese Adolescents 11 - 12 Years Old

Phase 3

Completed

Conditions: Diphtheria
Tetanus
Pertussis

Interventions: Biological: Diphtheria and Tetanus toxoids adsorbed

First Posted Date: 2014-03-17

Last Posted Date: 2017-05-30

Lead Sponsor: Sanofi Pasteur, a Sanofi Company

Target Recruit Count: 534

Registration Number: NCT02089347

Study of Tetanus and Diphtheria Toxoids Adsorbed Combined With Component Pertussis Vaccine and Inactivated Poliomyelitis

Phase 2

Completed

Conditions: Diphtheria
Tetanus
Poliomyelitis
Hepatitis B
Pertussis

Interventions: Biological: Tetanus and Diphtheria Toxoids Adsorbed Combined with Component Pertussis Vaccine and IPV
Biological: Hepatitis B vaccine

First Posted Date: 2014-01-20

Last Posted Date: 2015-03-25

Lead Sponsor: Sanofi Pasteur, a Sanofi Company

Target Recruit Count: 277

Registration Number: NCT02040636

Study of the Immunogenicity and Safety of a Challenge Dose of HBVAXPRO in Healthy Children Vaccinated 10 Years Ago With 3 Doses of HEXAVAC or INFANRIX HEXA

Phase 3

Completed

Conditions: Hepatitis B
Virus Diseases

Interventions: Biological: HBVAXPRO 5µg

First Posted Date: 2013-12-17

Last Posted Date: 2017-09-11

Lead Sponsor: Sanofi Pasteur, a Sanofi Company

Target Recruit Count: 751

Registration Number: NCT02012998

Locations: 🇮🇹
Sanofi Pasteur MSD Investigational Site 004, Bologna, Italy
🇮🇹
Sanofi Pasteur MSD Investigational Site 009, Cagliari, Italy
🇮🇹
Sanofi Pasteur MSD Investigational Site 005, Capannori, Italy

and more 7 locations

Safety of Two Doses of Avaxim® 80U Pediatric (Inactivated Hepatitis A Vaccine) in Toddlers, Children and Adolescents

Phase 4

Completed

Conditions: Hepatitis A
Hepatitis A Virus

First Posted Date: 2013-12-13

Last Posted Date: 2015-10-01

Lead Sponsor: Sanofi Pasteur, a Sanofi Company

Target Recruit Count: 355

Registration Number: NCT02011763

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy